Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting
Calidi Biotherapeutics announced acceptance of two abstracts for online publication at the 2026 ASCO Annual Meeting, showcasing its RedTail platform's ability to deliver systemic virotherapy targeting tumors. Preclinical data on lead candidates CLD-401 and CLD-501 demonstrate promising immune activation and therapeutic potential in solid tumors wit…